播散性talimogene laherparepvec疱疹感染后持久的黑色素瘤控制。 - Suppr

Suppr

超能文献

Durable melanoma control following disseminated talimogene laherparepvec herpetic infection.

作者信息

Shmuylovich Leonid, McEvoy Aubriana M, Fields Ryan C, Hernandez-Aya Leonel, Ansstas George, Chen David Y

机构信息

Division of Dermatology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri.

Department of Surgery, Washington University School of Medicine, St. Louis, Missouri.

出版信息

JAAD Case Rep. 2022 Sep 21;29:131-133. doi: 10.1016/j.jdcr.2022.09.012. eCollection 2022 Nov.

DOI:10.1016/j.jdcr.2022.09.012

PMID:36262357

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9574543/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fa45/9574543/de3a8317cd57/gr1.jpg

相似文献

Durable melanoma control following disseminated talimogene laherparepvec herpetic infection.

JAAD Case Rep. 2022 Sep 21;29:131-133. doi: 10.1016/j.jdcr.2022.09.012. eCollection 2022 Nov.

The safety of talimogene laherparepvec for the treatment of advanced melanoma.

Expert Opin Drug Saf. 2017 Feb;16(2):265-269. doi: 10.1080/14740338.2017.1274729. Epub 2016 Dec 28.

Four cases of disseminated herpes simplex virus following talimogene laherparepvec injections for unresectable metastatic melanoma.

JAAD Case Rep. 2023 Jan 27;33:56-58. doi: 10.1016/j.jdcr.2022.12.023. eCollection 2023 Mar.

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma.

EBioMedicine. 2019 Sep;47:89-97. doi: 10.1016/j.ebiom.2019.07.066. Epub 2019 Aug 10.

Metastatic melanoma with diffuse melanosis histologically after stable response to talimogene laherparepvec therapy.

JAAD Case Rep. 2018 Apr 4;4(4):379-381. doi: 10.1016/j.jdcr.2018.01.023. eCollection 2018 May.

Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma.

Melanoma Res. 2018 Feb;28(1):44-51. doi: 10.1097/CMR.0000000000000399.

Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers.

Semin Oncol. 2016 Dec;43(6):638-646. doi: 10.1053/j.seminoncol.2016.10.005. Epub 2016 Oct 27.

Talimogene Laherparepvec: A Review in Unresectable Metastatic Melanoma.

BioDrugs. 2016 Oct;30(5):461-468. doi: 10.1007/s40259-016-0189-y.

Talimogene Laherparepvec: An Oncolytic Virus Therapy for Melanoma.

Ann Pharmacother. 2017 Aug;51(8):675-681. doi: 10.1177/1060028017702654. Epub 2017 Mar 28.

Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study.

J Immunother Cancer. 2016 Mar 15;4:12. doi: 10.1186/s40425-016-0116-2. eCollection 2016.

引用本文的文献

A Novel Intersection: Cytomegalovirus Gastritis Following Cemiplimab and Talimogene Laherparepvec in a Patient With Advanced Cutaneous Squamous Cell Carcinoma.

Clin Case Rep. 2024 Dec 15;12(12):e9632. doi: 10.1002/ccr3.9632. eCollection 2024 Dec.

Advances in cell-based delivery of oncolytic viruses as therapy for lung cancer.

Mol Ther Oncol. 2024 Feb 29;32(1):200788. doi: 10.1016/j.omton.2024.200788. eCollection 2024 Mar 21.

Liver transplant patient with in-transit squamous cell carcinoma treated with talimogene laherparepvec.

JAAD Case Rep. 2023 Aug 9;40:53-57. doi: 10.1016/j.jdcr.2023.07.033. eCollection 2023 Oct.

Four cases of disseminated herpes simplex virus following talimogene laherparepvec injections for unresectable metastatic melanoma.

JAAD Case Rep. 2023 Jan 27;33:56-58. doi: 10.1016/j.jdcr.2022.12.023. eCollection 2023 Mar.

本文引用的文献

Disseminated Herpes Infection Following Talimogene Laherparepvec Administration.

JAMA Dermatol. 2022 Apr 1;158(4):456-457. doi: 10.1001/jamadermatol.2022.0020.

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanoma.

EBioMedicine. 2019 Sep;47:89-97. doi: 10.1016/j.ebiom.2019.07.066. Epub 2019 Aug 10.

Observational study of talimogene laherparepvec use for melanoma in clinical practice in the United States (COSMUS-1).

Melanoma Manag. 2019 Jul 3;6(2):MMT19. doi: 10.2217/mmt-2019-0012.

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma.

J Immunother Cancer. 2019 Jun 6;7(1):145. doi: 10.1186/s40425-019-0623-z.

High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a).

Int J Cancer. 2019 Aug 15;145(4):974-978. doi: 10.1002/ijc.32172. Epub 2019 Feb 21.

Real-World Outcomes of Talimogene Laherparepvec Therapy: A Multi-Institutional Experience.

J Am Coll Surg. 2019 Apr;228(4):644-649. doi: 10.1016/j.jamcollsurg.2018.12.027. Epub 2019 Jan 25.

The twilight of immunity: emerging concepts in aging of the immune system.

Nat Immunol. 2018 Jan;19(1):10-19. doi: 10.1038/s41590-017-0006-x. Epub 2017 Dec 14.

Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma.

Melanoma Res. 2018 Feb;28(1):44-51. doi: 10.1097/CMR.0000000000000399.

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.

J Clin Oncol. 2015 Sep 1;33(25):2780-8. doi: 10.1200/JCO.2014.58.3377. Epub 2015 May 26.

The three Es of cancer immunoediting.

Annu Rev Immunol. 2004;22:329-60. doi: 10.1146/annurev.immunol.22.012703.104803.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验